APIXABAN and COVID 19

Overview

COVID 19 is the #17 most commonly reported adverse reaction for APIXABAN, manufactured by Amneal Pharmaceuticals of New York LLC. There are 1,555 FDA adverse event reports linking APIXABAN to COVID 19. This represents approximately 1.5% of all 106,298 adverse event reports for this drug.

Patients taking APIXABAN who experience covid 19 should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.

Reporting Frequency

COVID 19 is a less commonly reported adverse event for APIXABAN, but still significant enough to appear in the safety profile.

Other Side Effects of APIXABAN

In addition to covid 19, the following adverse reactions have been reported for APIXABAN:

• ATRIAL FIBRILLATION — 3,970 reports
• DYSPNOEA — 3,599 reports
• CEREBROVASCULAR ACCIDENT — 3,508 reports
• THROMBOSIS — 2,806 reports
• OFF LABEL USE — 2,693 reports
• CARDIAC DISORDER — 2,509 reports
• DEATH — 2,332 reports
• FALL — 2,287 reports
• FATIGUE — 2,193 reports
• DIZZINESS — 1,929 reports

Other Drugs Associated with COVID 19

The following drugs have also been linked to covid 19 in FDA adverse event reports:

Does APIXABAN cause COVID 19?

COVID 19 has been reported as an adverse event in 1,555 FDA reports for APIXABAN. This does not prove causation, but indicates an association observed in post-market surveillance data.

How common is COVID 19 with APIXABAN?

COVID 19 accounts for approximately 1.5% of all adverse event reports for APIXABAN, making it a notable side effect.

What should I do if I experience COVID 19 while taking APIXABAN?

If you experience covid 19 while taking APIXABAN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.

Related Pages